Market Research Logo

Shire Plc - Product Pipeline Review - 2016

Shire Plc - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Shire Plc - Product Pipeline Review - 2016’, provides an overview of the Shire Plc’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Shire Plc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Shire Plc
  • The report provides overview of Shire Plc including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Shire Plc’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Shire Plc’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
  • Evaluate Shire Plc’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Shire Plc
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Shire Plc’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Shire Plc Snapshot
Shire Plc Overview
Key Information
Key Facts
Shire Plc - Research and Development Overview
Key Therapeutic Areas
Shire Plc - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
Shire Plc - Pipeline Products Glance
Shire Plc - Late Stage Pipeline Products
Pre-Registration Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Shire Plc - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Shire Plc - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Shire Plc - Unknown Stage Pipeline Products
Unknown Products/Combination Treatment Modalities
Shire Plc - Drug Profiles
guanfacine hydrochloride ER
Product Description
Mechanism of Action
R&D Progress
lifitegrast
Product Description
Mechanism of Action
R&D Progress
parathyroid hormone
Product Description
Mechanism of Action
R&D Progress
agalsidase alfa
Product Description
Mechanism of Action
R&D Progress
budesonide
Product Description
Mechanism of Action
R&D Progress
C1 esterase inhibitor (human)
Product Description
Mechanism of Action
R&D Progress
icatibant acetate
Product Description
Mechanism of Action
R&D Progress
lanadelumab
Product Description
Mechanism of Action
R&D Progress
lisdexamfetamine dimesylate
Product Description
Mechanism of Action
R&D Progress
prucalopride succinate
Product Description
Mechanism of Action
R&D Progress
SHP-465
Product Description
Mechanism of Action
R&D Progress
teduglutide (recombinant)
Product Description
Mechanism of Action
R&D Progress
idursulfase
Product Description
Mechanism of Action
R&D Progress
maribavir
Product Description
Mechanism of Action
R&D Progress
mecasermin rinfabate (recombinant)
Product Description
Mechanism of Action
R&D Progress
revexepride
Product Description
Mechanism of Action
R&D Progress
SHP-610
Product Description
Mechanism of Action
R&D Progress
SHP-625
Product Description
Mechanism of Action
R&D Progress
SHP-635
Product Description
Mechanism of Action
R&D Progress
SHP-640
Product Description
Mechanism of Action
R&D Progress
VP-20621
Product Description
Mechanism of Action
R&D Progress
SHP-611
Product Description
Mechanism of Action
R&D Progress
SHP-622
Product Description
Mechanism of Action
R&D Progress
SHP-623
Product Description
Mechanism of Action
R&D Progress
SHP-627
Product Description
Mechanism of Action
R&D Progress
volixibat potassium
Product Description
Mechanism of Action
R&D Progress
Drugs for Rare Diseases
Product Description
Mechanism of Action
R&D Progress
DX-2507
Product Description
Mechanism of Action
R&D Progress
DX-4012
Product Description
Mechanism of Action
R&D Progress
Gene Therapy to Activate GTP Cyclohydrolase I for Parkinson's Disease
Product Description
Mechanism of Action
R&D Progress
HTL-1071
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies for Genetic Diseases
Product Description
Mechanism of Action
R&D Progress
SC-435
Product Description
Mechanism of Action
R&D Progress
SHP-630
Product Description
Mechanism of Action
R&D Progress
SHP-637
Product Description
Mechanism of Action
R&D Progress
SHP-639
Product Description
Mechanism of Action
R&D Progress
SHP-641
Product Description
Mechanism of Action
R&D Progress
etiguanfacine
Product Description
Mechanism of Action
R&D Progress
Shire Plc - Pipeline Analysis
Shire Plc - Pipeline Products by Target
Shire Plc - Pipeline Products by Route of Administration
Shire Plc - Pipeline Products by Molecule Type
Shire Plc - Pipeline Products by Mechanism of Action
Shire Plc - Recent Pipeline Updates
Shire Plc - Dormant Projects
Shire Plc - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
NRP-290
SPD-452
SPD-453
SPD-756
ALX-0646
BMN-185
C1 esterase inhibitor (human)
CX-516
ecallantide
HCV-796
HGT-1111
HGT-2610
icatibant acetate
isovaleramide
lisdexamfetamine dimesylate
mesalamine ER
metoclopramide hydrochloride
ramatercept
SHP-557
SHP-613
SHP-628
SPD-491
SPD-554
SPD-556
valrocemide
Shire Plc - Company Statement
Shire Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Shire Plc - Key Manufacturing Facilities
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Shire Plc, Key Information
Shire Plc, Key Facts
Shire Plc - Pipeline by Indication, 2016
Shire Plc - Pipeline by Stage of Development, 2016
Shire Plc - Monotherapy Products in Pipeline, 2016
Shire Plc - Partnered Products in Pipeline, 2016
Shire Plc - Partnered Products/ Combination Treatment Modalities, 2016
Shire Plc - Out-Licensed Products in Pipeline, 2016
Shire Plc - Out-Licensed Products/ Combination Treatment Modalities, 2016
Shire Plc - Pre-Registration, 2016
Shire Plc - Phase III, 2016
Shire Plc - Phase II, 2016
Shire Plc - Phase I, 2016
Shire Plc - Preclinical, 2016
Shire Plc - Unknown, 2016
Shire Plc - Pipeline by Target, 2016
Shire Plc - Pipeline by Route of Administration, 2016
Shire Plc - Pipeline by Molecule Type, 2016
Shire Plc - Pipeline Products by Mechanism of Action, 2016
Shire Plc - Recent Pipeline Updates, 2016
Shire Plc - Dormant Developmental Projects,2016
Shire Plc - Discontinued Pipeline Products, 2016
Shire Plc, Other Locations
Shire Plc, Subsidiaries
Shire Plc, Key Manufacturing Facilities
List of Figures
Shire Plc - Pipeline by Top 10 Indication, 2016
Shire Plc - Pipeline by Stage of Development, 2016
Shire Plc - Monotherapy Products in Pipeline, 2016
Shire Plc - Partnered Products in Pipeline, 2016
Shire Plc - Out-Licensed Products in Pipeline, 2016
Shire Plc - Pipeline by Top 10 Target, 2016
Shire Plc - Pipeline by Route of Administration, 2016
Shire Plc - Pipeline by Top 10 Molecule Type, 2016
Shire Plc - Pipeline Products by Top 10 Mechanism of Action, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report